31
Lilly K, Kerner J, Bieber LL.
Inhibition of mitochondrial and microsomal carnitine acyltransferases by Etomoxiryl-CoA. Annual Meeting of ASBMB 1988.

32
Lopaschuk GD, Wall SR.
Stimulation of glucose oxidation by carnitine palmitoyltransferase 1 inhibition during reperfusion of ischemic myocardium. Annual Meeting of Alberta Heritage Foundation for Medical Research 1988, Abstract.

33
Lopaschuk GD, Wall SR, Olley PM Davies NJ.
Etomoxir, a Carnitine Palmitoyltransferase I Inhibitor, Protects Hearts From Fatty Acid-Induced Ischemic Injury Independent of Changes in Long Chain Acylcarnitines. Circ. Res. 63 (1988) 6, 1036-1043.

34
Lopaschuk GD.
Carnitine acyltransferase I inhibition prevents fatty acid induced injury in ischemic hearts from diabetic rats. Annual Meeting of the Canadian Cardiovascular Society, Montreal, Quebec October 1988.

35
Lopaschuk GD.
Palmitate and glucose oxidation during reperfusion of ischemic myocardium. 2nd Intenational Symposium on Lipid Metabolism in the Normoxic and Ischemic Heart, Maastricht, The Netherlands, September 1988

36
Reaven GM, Chang H, Hoffman BB.
Additive Hypoglcemic Effects of Drugs That Modify Free-Fatty Acid Metabolism by Different Mechanisms in Rats With Streptozotocin-Induced Diabetes. Diabetes 37 (1988) 28-32.

37
Selby PL.
Etomoxir ameliorates diabetes in the streptozotocin treated rat. 24th Annual Meeting of EASD, Paris, France, September 1988.

38
Taylor R, Agius L.
The biochemistry of diabetes. Review Article. Biochem. J. 250 (1988) 625-640.

39
Wolf HPO.
Metabolische Kontrolle durch Etomoxir bei genetisch-diabetischen Mäusen (db/db). 23. Jahrestagung der Deutschen Diabetes-Gesellschaft, Tübingen Mai 1988.

40
Wolf HPO.
Metabolic control and prolongation of life expectancy by Etomoxir in the diabetic mouse (db/db). Diab. Res. Clin. Pract. 5 (1988) S619.